Reconfiguration of competencies as a response to the emergence of disruptive new markets – evidence from Indian pharmaceutical firms
This paper examines the response of Indian firms to the emergence of a new disruptive market segment resulting from evolving biosimilar regulation and saturation of existing generics markets. Using novel analytical tools such as a technology–market capability matrix we show technological trajectories and heterogeneity in firm strategies employed by incumbent firms to compete in the biosimilars market. Analysis reveals that entry into emerging country markets and R&D collaborations formed core elements of experimentation with strategy.
|Year of Conference||
The International Joseph Schumpeter Society 15th ISS Conference: Foundations of Economic Change - Behaviour, Interaction and Aggregate Outcomes